ATE218859T1 - Liganden des neuropeptids y - Google Patents
Liganden des neuropeptids yInfo
- Publication number
- ATE218859T1 ATE218859T1 AT97939524T AT97939524T ATE218859T1 AT E218859 T1 ATE218859 T1 AT E218859T1 AT 97939524 T AT97939524 T AT 97939524T AT 97939524 T AT97939524 T AT 97939524T AT E218859 T1 ATE218859 T1 AT E218859T1
- Authority
- AT
- Austria
- Prior art keywords
- neuropeptide
- ligands
- formula
- agonists
- regulators
- Prior art date
Links
- 101710151321 Melanostatin Proteins 0.000 title abstract 3
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title abstract 3
- 239000003446 ligand Substances 0.000 title abstract 2
- 102100028427 Pro-neuropeptide Y Human genes 0.000 title 1
- 102400000064 Neuropeptide Y Human genes 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2579196P | 1996-08-23 | 1996-08-23 | |
| PCT/US1997/014854 WO1998007420A1 (en) | 1996-08-23 | 1997-08-22 | Neuropeptide-y ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE218859T1 true ATE218859T1 (de) | 2002-06-15 |
Family
ID=21828075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97939524T ATE218859T1 (de) | 1996-08-23 | 1997-08-22 | Liganden des neuropeptids y |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6849733B1 (de) |
| EP (1) | EP0984778B1 (de) |
| JP (1) | JP2001502296A (de) |
| AT (1) | ATE218859T1 (de) |
| AU (1) | AU4159297A (de) |
| CA (1) | CA2268051A1 (de) |
| DE (1) | DE69713402T2 (de) |
| DK (1) | DK0984778T3 (de) |
| ES (1) | ES2176776T3 (de) |
| PT (1) | PT984778E (de) |
| WO (1) | WO1998007420A1 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9703414D0 (sv) * | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
| SE9802206D0 (sv) * | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
| SE9802207D0 (sv) * | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
| EP1033366A3 (de) * | 1999-02-18 | 2000-12-27 | Pfizer Products Inc. | Amid-Derivate mit Neuropeptid Y (NPY) -antagonistischer Wirkung |
| US6774243B2 (en) | 1999-08-24 | 2004-08-10 | Agouron Pharmaceuticals, Inc. | Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates |
| US6355807B1 (en) | 1999-08-24 | 2002-03-12 | Agouron Pharmaceuticals, Inc. | Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates |
| DZ3415A1 (fr) | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
| JP2004522705A (ja) * | 2000-10-30 | 2004-07-29 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | アミジノ−尿素セロトニン受容体リガンドおよび組成物、その医薬的使用およびその合成方法 |
| WO2002081443A1 (en) | 2001-04-09 | 2002-10-17 | Chiron Corporation | Novel guanidino compounds |
| PT1551834E (pt) | 2002-05-23 | 2010-09-30 | Novartis Vaccines & Diagnostic | Compostos de quinazolinona substituídos |
| EP1620091B1 (de) | 2003-05-05 | 2010-03-31 | Probiodrug AG | Glutaminylcyclase-hemmer |
| EP1651229A1 (de) | 2003-05-23 | 2006-05-03 | Chiron Corporation | Guanidino-substituierte chinazolinon-verbindungen als mc4-r agonisten |
| AU2004290499C1 (en) | 2003-11-03 | 2011-02-24 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| US7368453B2 (en) | 2003-11-19 | 2008-05-06 | Chiron Corporation | Quinazolinone compounds with reduced bioaccumulation |
| WO2005075436A2 (en) | 2004-02-05 | 2005-08-18 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| EP1877076A4 (de) * | 2005-04-15 | 2012-02-01 | Regenertech Pty Ltd | Verwendung von neuropeptid y (npy) sowie von agonisten und antagonisten davon zur geweberegeneration |
| US7273882B2 (en) * | 2005-06-21 | 2007-09-25 | Bristol-Myers Squibb Company | Aminoacetamide acyl guanidines as β-secretase inhibitors |
| PT2404919E (pt) | 2005-11-08 | 2013-10-22 | Vertex Pharma | Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US7657504B2 (en) * | 2006-10-10 | 2010-02-02 | Microsoft Corporation | User interface for displaying images of sights |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| EP2164840A2 (de) | 2007-05-09 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Modulatoren von cftr |
| CA2989620C (en) | 2007-12-07 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| HUE049642T2 (hu) | 2007-12-07 | 2020-09-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái |
| CA2716109C (en) | 2008-02-28 | 2016-07-19 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
| PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
| ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| MX2012010470A (es) | 2010-03-10 | 2012-10-09 | Probiodrug Ag | Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5). |
| ES2900353T3 (es) | 2010-04-07 | 2022-03-16 | Vertex Pharma | Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| EP2686313B1 (de) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazolderivate als glutaminylcyclase-hemmer |
| NZ727015A (en) | 2012-01-25 | 2017-12-22 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| CA2930199C (en) | 2013-11-12 | 2022-10-25 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
| HUE055423T2 (hu) | 2014-11-18 | 2021-11-29 | Vertex Pharma | Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére |
| WO2018097126A1 (ja) * | 2016-11-25 | 2018-05-31 | 日本曹達株式会社 | グアニジン化合物および殺菌剤 |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58501467A (ja) * | 1981-08-24 | 1983-09-01 | ロウラ− インタ−ナシヨナル（オ−バ−シ−ズ） インコ−ポレ−テツド | 伝染病の治療 |
| US4562209A (en) * | 1981-08-24 | 1985-12-31 | William H. Rorer, Inc. | Promotion of feed efficiency in animals |
| US5380945A (en) * | 1989-06-21 | 1995-01-10 | Abbott Laboratories | Guanidino compounds as regulators of nitric oxide synthase |
| EP0448765B1 (de) * | 1990-03-30 | 1994-08-17 | HEUMANN PHARMA GMBH & CO | Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung |
| US5583238A (en) * | 1990-11-19 | 1996-12-10 | G. D. Searle & Co. | Method for making intermediates useful in synthesis of retroviral protease inhibitors |
| US5482947A (en) | 1990-11-19 | 1996-01-09 | Talley; John J. | Retroviral protease inhibitors |
| DE4326465A1 (de) * | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE4301452A1 (de) * | 1993-01-20 | 1994-07-21 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| FR2701480B1 (fr) | 1993-02-15 | 1995-05-24 | Sanofi Elf | Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
| WO1996012489A1 (en) | 1994-10-20 | 1996-05-02 | Eli Lilly And Company | Bicyclic neuropeptide y receptor antagonists |
| US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| WO1996014307A1 (en) | 1994-11-07 | 1996-05-17 | Pfizer Inc. | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
-
1997
- 1997-08-22 WO PCT/US1997/014854 patent/WO1998007420A1/en not_active Ceased
- 1997-08-22 US US08/916,527 patent/US6849733B1/en not_active Expired - Fee Related
- 1997-08-22 PT PT97939524T patent/PT984778E/pt unknown
- 1997-08-22 DE DE69713402T patent/DE69713402T2/de not_active Expired - Fee Related
- 1997-08-22 AU AU41592/97A patent/AU4159297A/en not_active Abandoned
- 1997-08-22 DK DK97939524T patent/DK0984778T3/da active
- 1997-08-22 AT AT97939524T patent/ATE218859T1/de not_active IP Right Cessation
- 1997-08-22 JP JP10511019A patent/JP2001502296A/ja not_active Ceased
- 1997-08-22 CA CA002268051A patent/CA2268051A1/en not_active Abandoned
- 1997-08-22 EP EP97939524A patent/EP0984778B1/de not_active Expired - Lifetime
- 1997-08-22 ES ES97939524T patent/ES2176776T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001502296A (ja) | 2001-02-20 |
| DK0984778T3 (da) | 2002-09-16 |
| DE69713402T2 (de) | 2002-11-07 |
| EP0984778A4 (de) | 2000-06-07 |
| EP0984778A1 (de) | 2000-03-15 |
| EP0984778B1 (de) | 2002-06-12 |
| WO1998007420A1 (en) | 1998-02-26 |
| CA2268051A1 (en) | 1998-02-26 |
| PT984778E (pt) | 2002-09-30 |
| DE69713402D1 (de) | 2002-07-18 |
| US6849733B1 (en) | 2005-02-01 |
| ES2176776T3 (es) | 2002-12-01 |
| AU4159297A (en) | 1998-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69713402D1 (de) | Liganden des neuropeptids y | |
| UY34152A (es) | ?oxazolidinonas substituidas y su uso?. | |
| SK86699A3 (en) | Nitrogen containing heteroaromatics as factor xa inhibitors | |
| EP0599532A3 (de) | Härtbare Einkomponenten-Organosiloxanzusammensetzungen. | |
| DK0572166T3 (da) | Hidtil ukendte 7beta-substitueret-4-aza-5beta-androstan-3-oner som 5beta-reduktaseinhibitorer | |
| AU1980997A (en) | Synthetic Multimerizing Agents | |
| TR199901653T2 (xx) | Fitalazinonlar. | |
| BG104670A (en) | 4-(2-keto-1-benzimidazolinyl)piperidinne compounds as orl1-receptor agonists | |
| BR9808491A (pt) | Compostos calcilìticos | |
| ATE228111T1 (de) | M-amidinophenyl-analoga als faktor-xa-inhibitoren | |
| BG103310A (en) | Benzonaphthyridins as bronchial therapeutical means | |
| IT1269176B (it) | Eterobicicli ad attivita' fungicida | |
| SE0004245D0 (sv) | Novel compounds and their use | |
| SG52766A1 (en) | Organic compounds | |
| TR199903014T2 (xx) | 5-HT1F Agonistleri olarak yararl� karboksamitler. | |
| NO981393D0 (no) | Guanidinoproteasehemmere | |
| BG105539A (bg) | Елетриптан хидробромид монохидрат | |
| GB2324091A (en) | Metalloproteinase inhibitors | |
| DK1204659T3 (da) | Serotonerge benzofuraner | |
| RU95106653A (ru) | Производные 2-имидазолин-5-онов и 2-имидазолин-5-тионов и фунгицидные композиции на их основе | |
| DK1377574T3 (da) | 6-phenylbenzonaphtyridiner | |
| EA199900534A1 (ru) | Имидазопиридазины | |
| ATE280169T1 (de) | Serotonerge benzothiophene | |
| TR200100133T2 (tr) | FKBP İnhibitörleri | |
| ES2103794T3 (es) | Pirazolinas, pirazolidinas e hidrazinas artropodicidas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |